We're seeing increasing interest from clinicians who plan to incorporate psilocybin treatments into their mental health offerings. Our collaborations are indications of this interest, and we'll continue to develop commercial models that enable rapid, scalable, broad and equitable access to COMP360 if approved. In closing, with our strong balance sheet, we are focused on execution of our Phase III program in treatment resistant depression. This will be an exciting year for COMPASS Pathways and we look forward to updating you on our progress over the coming year. Thank you again for your participation on today's call. And we'll now turn to Q&A. So I will hand the call back to the operator. Thanks.